Inactive Instrument

Miromatrix Medical Inc.

Equities

MIRO

US60471P1084

Biotechnology & Medical Research

Miromatrix Announces CEO Jeff Ross to Expand Role by Resuming Leadership of R&D

June 01, 2023 at 04:01 pm EDT

Miromatrix Medical Inc. announced that Miromatrix and John Barry have mutually agreed to end his employment as Vice President of Research and Development effective on or around June 13, 2023, and that Jeff Ross, Ph.D., Chief
Executive Officer, will assume leadership responsibilities for the R&D organization.

Latest news about Miromatrix Medical Inc.

Miromatrix Medical Inc. Announces Directorate Changes	Dec. 18	CI
Miromatrix Medical Inc.(NasdaqCM:MIRO) dropped from S&P TMI Index	Dec. 18	CI
Miromatrix Medical Inc.(NasdaqCM:MIRO) dropped from NASDAQ Composite Index	Dec. 13	CI
United Therapeutics Corporation completed the acquisition of Miromatrix Medical Inc. from Gagnon Securities, LLC and others	Dec. 12	CI
United Therapeutics, Miromatrix Medical Report Successful Tender Offer	Dec. 12	MT
Miromatrix Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sector Update: Health Care Stocks Gain Late Afternoon	23-10-30	MT
Top Midday Gainers	23-10-30	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-10-30	MT
Sector Update: Health Care	23-10-30	MT
United Therapeutics to Acquire Miromatrix Medical	23-10-30	MT
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	23-10-30	MT
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday	23-10-30	MT
Top Premarket Gainers	23-10-30	MT
United Therapeutics To Acquire Miromatrix Medical	23-10-30	RE
Transcript : Miromatrix Medical Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Miromatrix Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Miromatrix Medical Inc.(NasdaqCM:MIRO) added to Russell Microcap Value Index	23-06-23	CI
Miromatrix Medical Inc.(NasdaqCM:MIRO) added to Russell 3000E Value Index	23-06-23	CI
Certain Restricted Stock Units of Miromatrix Medical Inc. are subject to a Lock-Up Agreement Ending on 6-JUN-2023.	23-06-05	CI
Certain Warrants of Miromatrix Medical Inc. are subject to a Lock-Up Agreement Ending on 6-JUN-2023.	23-06-05	CI
Certain Options of Miromatrix Medical Inc. are subject to a Lock-Up Agreement Ending on 6-JUN-2023.	23-06-05	CI
Certain Common Stock of Miromatrix Medical Inc. are subject to a Lock-Up Agreement Ending on 6-JUN-2023.	23-06-05	CI
Miromatrix Announces CEO Jeff Ross to Expand Role by Resuming Leadership of R&D	23-06-01	CI
Piper Sandler Adjusts Price Target on Miromatrix Medical to $3 From $6, Keeps Overweight Rating	23-05-12	MT

Chart Miromatrix Medical Inc.

Duration

Period

More charts

Company Profile

Miromatrix Medical Inc. is a life sciences company. The Company is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company's technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research